BackMeribank Biotech , Ltd Overview

Meribank Biotech , Ltd Profit Margin

Meribank Biotech , Ltd (4724.TWO) has a profit margin of -22.56%, below the Healthcare sector average of 17.63%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-38.83%
↓ 410.23% YoY

As of Jun 2026

Annual Profit Margin (TTM)

-22.56%
↑ 52.99% YoY

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Meribank Biotech , Ltd (4724.TWO) FAQ

As of the most recent data (June 2026), 4724.TWO shows a profit margin of -22.56%. That compares with -47.99% in the prior-year period — up 53.0% year over year. That is below the Healthcare sector average of 17.63%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4724.TWO's profit margin is now -22.56% (was -47.99%) — a 53.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Meribank Biotech , Ltd is outperforming or lagging.

The Healthcare sector average profit margin is about 17.63%. Meribank Biotech , Ltd is at -22.56%, which is lower that average. That is roughly 228.0% below the sector mean. Use the comparison chart on this page to see how 4724.TWO stacks up against individual peers as well.

That compares with -47.99% in the prior-year period — up 53.0% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Meribank Biotech , Ltd with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Meribank Biotech , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -22.56%) with ownership activity and broader fundamentals.